PDL BioPharma, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
PDL BioPharma, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 8-month period ending 2020-08-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2021-03-29
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-12-31 was -$1.07M.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-06-30 was $0.00.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-03-31 was $1.07M.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was $0.00.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was -$858.00K.
- PDL BioPharma, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2016 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 8 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|---|
| 2020-08-31 | $0.00 10-K · filed 2021-03-29 | ||||
| 2019-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$1.07M derived: sum of 2 quarters · filed 2021-03-29 | -$1.07M derived: sum of 3 quarters · filed 2021-03-29 | $0.00 10-K · filed 2021-03-29 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $1.07M 10-Q · filed 2019-11-06 | -$644.00K derived: sum of 4 quarters · filed 2021-03-29 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.07M 10-Q · filed 2019-08-07 | -$644.00K derived: sum of 3 quarters · filed 2021-03-29 | -$572.00K derived: sum of 4 quarters · filed 2021-03-29 | |
| 2019-03-31 | $1.07M 10-Q · filed 2019-05-09 | -$644.00K derived: sum of 2 quarters · filed 2021-03-29 | -$572.00K derived: sum of 3 quarters · filed 2021-03-29 | ||
| 2018-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$1.64M derived: sum of 2 quarters · filed 2021-03-29 | -$858.00K 10-K · filed 2021-03-29 | ||
| 2018-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $857.00K 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $785.00K 10-Q · filed 2018-08-09 | ||||
| 2017-12-31 | $0.00 8-K · filed 2020-06-29 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-03-15 |